iPhone app to boost level of care for Crohn's

Share this article:
iPhone app to boost level of care for Crohn's
iPhone app to boost level of care for Crohn's
Patients with inflammatory bowel disease (IBD), Crohn's and ulcerative colitis can purchase a new iPhone application to keep an accurate record of their symptoms, and transfer the information to doctors.

The “GI Monitor” app was designed by Brett Shamosh, CEO and founder of WellApps, Inc. Shamosh was diagnosed with Crohn's disease at 16, and found traditional symptom logs cumbersome and unmanageable. After 18 years with the disease, Shamosh decided to use his background in digital media to create a technology for other patients with similar conditions.

“The application doesn't replace a doctor's diagnosis, but it can help to improve care,” said Shamosh. “Doctors can use patients' data and treat them accordingly.”

For $4.99 at Apple's online App Store, the GI Monitor allows patients to log the frequency of bowel movements, consistency and blood level of stool, and pain/stress levels. Keeping track of these symptoms on a mobile device makes sense, because “you have a PDA with you,” said Shamosh. The inputted information is organized into detailed logs which can be emailed directly to a doctor or family member.

Shamosh launched WellApps two months ago, and said the GI Monitor application was modular built, allowing the technology to be integrated into other apps currently in development for depression and hypertension.

Currently, Shamosh has no plans to incorporate advertising into the app, but says the idea can't be ruled out definitively. Shamosh plans to collect the data from GI Monitor users in the future, and provide it for doctors to help optimize treatment, he said. The GI Monitor app will be released for BlackBerry devices soon, according to a company statement. 
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...